NCT03162783View on ClinicalTrials.gov

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

July 6, 2017

Study Completion Date

July 6, 2017

Conditions
Dry Eye Syndromes
Interventions
DRUG

ADX-102 Ophthalmic Solution (0.5%)

ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.

DRUG

ADX-102 Ophthalmic Solution (0.1%)

ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.

DRUG

ADX-102 Ophthalmic Lipid Solution (0.5%)

ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY